Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials

Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical trials, the efficacy and safety of nivol...

Descripción completa

Detalles Bibliográficos
Autores principales: Knetki-Wróblewska, Magdalena, Kowalski, Dariusz M., Krzakowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408765/
https://www.ncbi.nlm.nih.gov/pubmed/32708936
http://dx.doi.org/10.3390/jcm9072273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408765/
https://www.ncbi.nlm.nih.gov/pubmed/32708936
http://dx.doi.org/10.3390/jcm9072273

Ejemplares similares